Recent contributions of structure-based drug design to the development of antibacterial compounds

Current Opinion in Microbiology - Tập 27 - Trang 133-138 - 2015
Bart L Staker1,2, Garry W Buchko1,3, Peter J Myler1,2,4,5
1Seattle Structural Genomics Center for Infectious Disease, United States
2Center for Infectious Disease Research (formerly Seattle Biomedical Research Institute), 307 Westlake Ave N, Suite 500, Seattle, WA 98109, United States
3Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, United States
4Department of Global Health, University of Washington, Seattle, WA 98195, United States
5Department of Biomedical Informatics and Health Education, University of Washington, Seattle, WA 98195, United States

Tài liệu tham khảo

Begley, 2011, Fragment screening of infectious disease targets in a structural genomics environment, Methods Enzymol, 493, 533, 10.1016/B978-0-12-381274-2.00021-2 Grinter, 2014, Challenges applications: and recent advances of protein-ligand docking in structure-based drug design, Molecules, 19, 10150, 10.3390/molecules190710150 Kuenemann, 2015, In silico design of low molecular weight protein–protein interaction inhibitors: overall concept and recent advances, Prog Biophys Mol Biol, 119, 20, 10.1016/j.pbiomolbio.2015.02.006 Kellici, 2015, Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors, Molecules, 20, 3868, 10.3390/molecules20033868 2014 Mensa, 2014, Comparative mechanistic studies of brilacidin: daptomycin, and the antimicrobial peptide LL16, Antimicrob Agents Chemother, 58, 5136, 10.1128/AAC.02955-14 Schneider, 2014, Cyclic lipopeptides as antibacterial agents—potent antibiotic activity mediated by intriguing mode of actions, Int J Med Microbiol, 304, 37, 10.1016/j.ijmm.2013.08.009 Weiss, 2014, In vivo assessment of SMT19969 in a hamster model of Clostridium difficile infection, Antimicrob Agents Chemother, 58, 5714, 10.1128/AAC.02903-14 Seddon, 2012, Drug design for ever: from hype to hope, J Comput Aided Mol Des, 26, 137, 10.1007/s10822-011-9519-9 Berman, 2000, The protein data bank, Nucleic Acids Res, 28, 235, 10.1093/nar/28.1.235 Stacy, 2011, Structural genomics of infectious disease drug targets: the SSGCID, Acta Crystallogr Sect F: Struct Biol Cryst Commun, 67, 979, 10.1107/S1744309111029204 Harris, 2015, Beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?, Lancet Infect Dis, 15, 475, 10.1016/S1473-3099(14)70950-8 Lahiri, 2013, Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases, Antimicrob Agents Chemother, 57, 2496, 10.1128/AAC.02247-12 Lahiri, 2014, Avibactam and class C beta-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance, Antimicrob Agents Chemother, 58, 5704, 10.1128/AAC.03057-14 Lahiri, 2015, Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48, ACS Chem Biol, 10, 591, 10.1021/cb500703p Karpiuk, 2013, Looking for the new preparations for antibacterial therapy. II. Clinical trials; new beta-lactam antibiotics and beta-lactamase inhibitors, Przegl Epidemiol, 67 Ehmann, 2012, Avibactam is a covalent: reversible, non-beta-lactam beta-lactamase inhibitor, Proc Natl Acad Sci U S A, 109, 11663, 10.1073/pnas.1205073109 Basarab, 2013, Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents, J Med Chem, 56, 8712, 10.1021/jm401208b Eakin, 2012, Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents, Antimicrob Agents Chemother, 56, 1240, 10.1128/AAC.05485-11 Brvar, 2012, Structure-based discovery of substituted 4,5-bithiazoles as novel DNA gyrase inhibitors, J Med Chem, 55, 6413, 10.1021/jm300395d Wüthrich, 1986 Barrett, 2013, The quiet renaissance of protein nuclear magnetic resonance, Biochemistry, 52, 1303, 10.1021/bi4000436 Pellecchia, 2002, NMR in drug discovery, Nat Rev Drug Discov, 1, 211, 10.1038/nrd748 Pellecchia, 2008, Perspectives on NMR in drug discovery: a technique comes of age, Nat Rev Drug Discov, 7, 738, 10.1038/nrd2606 Klages, 2007, NMR-based screening: a powerful tool in fragment-based drug discovery, Analyst, 132, 692, 10.1039/B709658P Dalvit, 2001, Unconditional pointer states from conditional master equations, Phys Rev Lett, 86, 373, 10.1103/PhysRevLett.86.373 Jahnke, 2001, Spin label enhanced NMR screening, J Am Chem Soc, 123, 3149, 10.1021/ja005836g Vanwetswinkel, 2005, TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery, Chem Biol, 12, 207, 10.1016/j.chembiol.2004.12.004 Fejzo, 1999, The SHAPES strategy: an NMR-based approach for lead generation in drug discovery, Chem Biol, 6, 755, 10.1016/S1074-5521(00)80022-8 Hajduk, 1997, One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules, J Am Chem Soc, 119, 12257, 10.1021/ja9715962 Mayer, 1999, Characterization of ligand binding by saturation transfer difference NMR spectroscopy, Angew Chem Int Ed, 38, 1784, 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q Wagstaff, 2013, Recent developments and applications of saturation transfer difference nuclear magnetic resonance (STD NMR) spectroscopy, Mol Biosyst, 9, 571, 10.1039/C2MB25395J Begley, 2014, A structural biology approach enables the development of antimicrobials targeting bacterial immunophilins, Antimicrob Agents Chemother, 58, 1458, 10.1128/AAC.01875-13 Yee, 2002, An NMR approach to structural proteomics, Proc Natl Acad Sci U S A, 99, 1825, 10.1073/pnas.042684599 Myler, 2009, The Seattle Structural Genomics Center for Infectious Disease (SSGCID), Infect Disord Drug Targets, 9, 493, 10.2174/187152609789105687 Habchi, 2014, Introducing protein intrinsic disorder, Chem Rev, 114, 6561, 10.1021/cr400514h Shuker, 1996, Discovering high-affinity ligands for proteins: SAR by NMR, Science, 274, 1531, 10.1126/science.274.5292.1531 Zuiderweg, 2002, Mapping protein–protein interactions in solution by NMR spectroscopy, Biochemistry, 41, 1, 10.1021/bi011870b Altmann, 2001, Microtubule-stabilizing agents: a growing class of important anticancer drugs, Curr Opin Chem Biol, 5, 424, 10.1016/S1367-5931(00)00225-8 Ojima, 2014, Drug discovery targeting cell division proteins: microtubules and FtsZ, Bioorg Med Chem, 22, 5060, 10.1016/j.bmc.2014.02.036 Lutkenhaus, 1997, Bacterial cell division and the Z ring, Annu Rev Biochem, 66, 93, 10.1146/annurev.biochem.66.1.93 Errington, 2003, Cytokinesis in bacteria, Microbiol Mol Biol Rev, 67, 52, 10.1128/MMBR.67.1.52-65.2003 Respicio, 2008, Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery, Tuberculosis (Edinb), 88, 420, 10.1016/j.tube.2008.03.001 Moy, 2000, Solution structure of ZipA: a crucial component of Escherichia coli cell division, Biochemistry, 39, 9146, 10.1021/bi0009690 Liu, 1999, Recruitment of ZipA to the division site by interaction with FtsZ, Mol Microbiol, 31, 1853, 10.1046/j.1365-2958.1999.01322.x Tsao, 2006, Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design, Bioorg Med Chem, 14, 7953, 10.1016/j.bmc.2006.07.050 Domadia, 2007, Inhibition of bacterial cell division protein FtsZ by cinnamaldehyde, Biochem Pharmacol, 74, 831, 10.1016/j.bcp.2007.06.029 Plaza, 2010, Chrysophaentins A-H: antibacterial bisdiarylbutene macrocycles that inhibit the bacterial cell division protein FtsZ, J Am Chem Soc, 132, 9069, 10.1021/ja102100h Marcelo, 2013, Interactions of bacterial cell division protein FtsZ with C8-substituted guanine nucleotide inhibitors. A combined NMR: biochemical and molecular modeling perspective, J Am Chem Soc, 135, 16418, 10.1021/ja405515r Baugh, 2015, Increasing the structural coverage of tuberculosis drug targets, Tuberculosis (Edinb), 95, 142, 10.1016/j.tube.2014.12.003 Kling, 2015, Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins, Science, 348, 1106, 10.1126/science.aaa4690 Shirude, 2013, Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis, ACS Chem Biol, 8, 519, 10.1021/cb300510w Stacy, 2015, Structural genomics support for infectious disease drug design, ACS Infect Dis, 1, 127, 10.1021/id500048p Baugh, 2013, Combining functional and structural genomics to sample the essential Burkholderia structome, PLoS One, 8, e53851, 10.1371/journal.pone.0053851